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The distribution of rs12979860 genotypes in our dataset was
similar to the population described by Petta et al., and typical for
a Caucasian population with 48.72% of the subjects homozygous
for the C allele, 41.54% heterozygous, and 9.74% homozygous for
the T allele.
However, in contrast to Petta et al., we did not ﬁnd a signiﬁ-
cant role of IL28B in relation to histological characteristics of
NAFLD (Table 1A). Results did not change substantially when
the analysis was adjusted for age, gender, DMdx, BMI and recruit-
ment site. The adjusted model, however, conﬁrmed the expected
role for BMI and diabetes mellitus in regard to histological
features of NAFLD (Table 1B).
Importantly, the trend for inﬂammation was reversed. While
64% of patients with increased inﬂammation in the study by
Petta et al. had the CC genotype, less than 40% of patients with
severe inﬂammation in our study had the CC genotype.
Furthermore, the NAFLD Activity Score, which showed borderline
signiﬁcance in the adjusted model (p = 0.0937), became less
signiﬁcant when an additive model (CC>CT>TT) was used
(p = 0.2243). Similar to the trend observed with inﬂammation,
the NAS tended to be lower in patients with rs12979860 CC geno-
type, and therefore in the opposite direction to the observation
by Petta et al.
Thus, in summary, our data do not show a signiﬁcant associ-
ation of IL28B and histological features in North American Cauca-
sian patients with NAFLD.
However, almost all of our patients were obese, while only
40% of the patients in Petta et al.’s study were obese (BMI >30).
It would, therefore, be interesting to know if the association
reported by Petta et al. change when stratifying their cohort
according to BMI group, <25, 25–30, and >30 BMI.Manal F. Abdelmalek
Allison Ashley-Koch
Michael A. Hauser
Cynthia A. Moylan
Herbert Pang
Anna Mae Diehl
Hans L. Tillmann⇑
Duke University, Durham, NC 27708, USA⇑Corresponding author. E-mail addresss: hans.tillmann@duke.eduFinancial support
This research was supported by the NIH Recovery Act Limited
Competition for NIH Grants: Research and Research Infrastruc-
ture Grand Opportunities (1 RC2 AA019399-01; PI: A.M. Diehl).
Cynthia D. Guy and Ayako Suzuki are additional members of
the DUKE go-Grant NAFLD working group.Reply to: ‘‘IL28B rs12979860 is not associated with histologic
features of NAFLD in a cohort of Caucasian North American patients’’IL28B rs12979860 genotype and liver damage in NAFLD: An
obesity-modulated effect?
To the Editor:
We recently reported a link between interleukin 28B (IL28B)
rs12979860 genotype and severity of liver disease, in a cohort
of 160 biopsy-proven non-alcoholic fatty liver disease (NAFLD)
patients, forty percent of them with obesity, and with a mean
age of 45.6 years [1]. In particular, we observed that the IL28B
CC genotype, associated in chronic hepatitis C (CHC) with a
higher rate of sustained virological response after antiviral ther-
apy [2], in NAFLD patients was independently associated with a
higher prevalence of moderate-severe liver lobular inﬂammation
and ﬁbrosis [1]. Our results were in line with other data on CHC
patients suggesting a link, even if not conﬁrmed in other studies,
between IL28B CC genotype and severity of liver disease [3,4].
In this complex picture, we read with great interest data
reported by Garrett and colleagues [5] on the association between
IL28B genotype and severity of histological features in NAFLD
patients. Speciﬁcally, the authors did not identify any association
among IL28B status and steatosis, inﬂammation, ballooning and
ﬁbrosis in their cohort of NAFLDpatients [5]. However, as correctly
highlighted by the same authors, they enrolled a cohort of severe
obese NAFLD patients evaluated for bariatric surgery [5], and
therefore very different from our enrolled cohort [1]. In particular,
it should be possible to assume that the genetic backgroundJournal of Hepatology 2013 vol. 58 j 402–404 403
tion where all patients have steatosis, mostly moderate-severe,
and second, differently from NAFLD patients, it is plausible to
suppose a strong interaction among HCV, IL28B genotype and
metabolic factors in the genesis of steatosis in CHC.
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Letters to the Editor
probably discriminating the ‘‘normal’’ from to the ‘‘morbidly
obese’’ NAFLD patient, could per se explain the different results
observed. In other words, it is plausible to state that ‘‘morbidly
obese NAFLD’’ is a disease different from ‘‘normal NAFLD’’. Beyond
these considerations, the results byGarret and colleagues [5] could
suggest an obesity-dependent effect of the IL28B genotype on liver
damage in NAFLD patients. Accordingly, we analyzed separately
non-obese (n = 94) and obese (n = 66) NAFLD patients, observing
that the association between IL28B genotype and severity of liver
damagewasmaintained only in non-obeseNAFLDpatients. In par-
ticular, among obese patients, a moderate-severe liver lobular
inﬂammation was observed in 17/28 IL28B CC, compared to 16/
38 IL28B TT/TC NAFLD patients (p = 0.13). By contrast, the preva-
lence of moderate-severe lobular inﬂammation was signiﬁcantly
higher in non-obese IL28B CC, compared to non-obese IL28B TT/
TC NAFLD patients (28/46 vs. 9/48; p <0.001). The protective role
of IL28B TT/TC genotype against moderate-severe lobular inﬂam-
mation was maintained at multivariate logistic analysis (OR
0.171, 95% C.I. 0.058–0.507, p = 0.001). As observed with lobular
inﬂammation, the association between liver ﬁbrosis and IL28B
genotype was present only in non-obese patients. Speciﬁcally, in
obese NAFLD patients, the prevalence of F2-F4 liver ﬁbrosis was
not signiﬁcantly different between IL28B CC and IL28B TT/TC
patients (17/28 vs. 22/38; p = 0.81). By contrast, the prevalence
of F2-F4was signiﬁcantly higher in non-obese IL28B CC, compared
to non-obese IL28B TT/TC NAFLD patients (25/46 vs. 14/48;
p = 0.01).
These data overall seem to suggest an effect of IL28B CC geno-
type only in patients at lower metabolic risk, and not in obese
patients, were the impact of metabolic alterations on NAFLD
severity probably overcomes the pathogenic role of genetic back-
ground. However, due to small sample of obese patients in our
cohort, a further validation is needed.
Finally, the lack of association between IL28B genotype and
severity of steatosis in our NAFLD group, which was instead
observed in CHC patients (protective role of IL28B C/C against ste-
atosis) [6] is not surprising. In fact, ﬁrst, we evaluated a popula-404 Journal of Hepatology 2013 vol. 58 j 402–404
